Gonadotrophin administration can benefit ovarian tissue grafted to the body wall: implications for human ovarian grafting.
Ovarian grafting provides a strategy for clinical infertility treatment and is starting to be used in conjunction with ovarian tissue storage for patients at risk of early ovarian failure. As patients are starting to return for their frozen stored tissue we need to ascertain how to maximise follicle survival when this tissue is grafted back to the patient. For research purposes ovarian tissue is commonly grafted to the kidney capsule as the rich capillary bed at this site favours rapid graft revascularization. This is however not an ideal site for natural conceptions or for the harvest of mature oocytes for in vitro fertilization. While oocytes would be relatively easy to recover from grafts on the abdominal wall or subcutaneous tissue graft revascularization at these sites is slower and evidence indicates that fewer follicles survive. As gonadotropins can upregulate angiogenic growth factors in the ovary this study was designed to test whether the administration of exogenous gonadotropins would increase the number of surviving follicles in grafts placed at less vascularised sites. We showed that exogenous gonadotrophins, given to either the donor or the recipient, could increase the number of developing follicles but the magnitude of this effect was influenced by the timing of the injections relative to the time of grafting.
Imthurn
B
B
Centre for Early Human Development, Monash Institute of Reproduction and Development, Monash University, Vic. 3168, Clayton, Australia.
Cox
S L
SL
Jenkin
G
G
Trounson
A O
AO
Shaw
J M
JM
D000009:Abdominal Muscles / Q000098:blood supply / Q000601:surgery; D000818:Animals; D002470:Cell Survival; D016228:Endothelial Growth Factors / Q000378:metabolism; D005260:Female; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage* / Q000494:pharmacology; D006801:Humans; D007274:Injections, Intraperitoneal; D007986:Luteinizing Hormone / Q000008:administration & dosage* / Q000494:pharmacology; D008222:Lymphokines / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D006080:Ovarian Follicle / Q000166:cytology* / Q000502:physiology; D010053:Ovary / Q000637:transplantation*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D008222:Lymphokines; D011994:Recombinant Proteins; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone